A recombinant humanized anti-insulin-like growth factor-receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts

International Journal of Cancer

Volumn 113, Issue 2, 2005, Pages 316-328

  Goetsch, Liliane ^a   Gonzalez, Alexandra ^a   Leger, Olivier ^a   Beck, Alain ^a   Pauwels, Petrus J ^a   Haeuw, Jean François ^a   Corvaia, Nathalie ^a  

^a Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Combined anti cancer therapy; Humanized antibody; Insulin like growth factor type I receptor

Indexed keywords

ANTIEPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; H7C10; NAVELBINE; RECOMBINANT ANTIBODY; RECOMBINANT HUMANIZED ANTIINSULIN LIKE GROWTH FACTOR RECEPTOR TYPE 1 ANTIBODY; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; DRUG INTERACTIONS; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 10344247119     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20543     Document Type: Article

References (76)

1. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73-82.
2. Van den Berg WB, Van der Kraan PM, Scharstuhl A, Van Beuningen HM. Growth factors and cartilage repair. Clin Orthop 2001;391:S244-50.
3. Trippel SB. Potential role of insulin-like growth factors in fracture healing. Clin Orthop 1998;355:S301-13.
4. MacGregor J, Parkhouse WS. The potential role of insulin-like growth factors in skeletal muscle regeneration. Can J Appl Physiol 1996;21:236-50.
5. Lal SO, Wolf SE, Herndon DN. Growth hormone, burns and tissue healing. Growth Horm IGF Res 2000;10:S39-43.
6. Singh P, Rubin N. Insulin-like growth factors and binding proteins in colon cancer. Gastroenterology 1993;105:1218-37.
7. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997;1332:F105-26.
8. De Meyts P, Wallach B, Christoffersen CT, Urso B, Gronskov K, Latus LJ, Yakushiji F, Ilondo MM, Shymko RM. The insulin-like growth factor-I receptor: structure, ligand-binding mechanism and signal transduction. Horm Res 1994;42:152-69.
9. LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995;122:54-9.
10. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor 1 receptor. Endocrinol Rev 1995;16:143-63.
11. Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 1998;69:21-7.
12. Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, Karl RC, Coppola D. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999;30:1128-33.
13. Railo MJ, Von Smitten K, Pekonen F. The prognostic value of insulin-like growth factor-I in breast cancer patients: results of a follow-up study on 126 patients. Eur J Cancer 1994;30A:307-11.
14. Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby A. The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 1997;183: 412-7.
15. Macauly VM, Teale JD, Everard MJ, Joshi GP, Smith IE, Millar JL. Somatomedin-C/insulin-like growth factor-I is a mitogen for human small cell lung cancer. Br J Cancer 1988;57:91-3.
16. Freed KA, Herington AC. Insulin-like growth factor-I and its autocrine role in growth of MCF-7 human breast cancer cells in culture. J Mol Endocrinol 1989;3:183-90.
17. Nakanishi Y, Mulshine JL, Kasprzyk PG, Natale RB, Maneckjee R, Avis I, Treston AM, Gazdar AF, Minna JD, Cuttitta F. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 1988;82:354-9.
18. Lee TC, Zhang Y, Aston C, Hintz R, Jagirdar J, Perle MA, Burt M, Rom WN. Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res 1993;53:2858-64.
19. Singh P. Insulin-like growth factor system in growth, development and carcinogenesis. J Clin Lig Assay 2000;23:214-32.
20. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 1993;90:11217-11221.
21. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, Rubin R, Efstratiadis A, Baserga R. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994; 14:3604-12.
22. Kulik G, Klippel A, Weber, MJ. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997;17:1595-606.
23. D'Ambrosio C, Valentinis B, Prisco M, Reiss K, Rubini M, Baserga R. Protective effect of the insulin-like growth factor I receptor on apoptosis induced by okadaic acid. Cancer Res 1997;57:3264-71.
24. Wu Y, Tewari M, Cui S, Rubin R. Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death. J Cell Physiol 1996;168:499-509.
25. Albanell J, Baselga J. Unraveling resistance to trastuzuMAb (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst 1996;93:1830-2.
26. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzuMAb (Herceptin). J Natl Cancer Inst 2001;93:1852-7.
27. Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 1989;49:6237-41.
28. Zia F, Jacobs S, Kull F Jr, Cuttitta F, Mulshine JL, Moody TW. Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. J Cell Biochem 1996;24:269-75.
29. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blattler WA, Chittenden T, Singh R. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003;63:5073-83.
30. Hailey J, Maxwell E, Koukouras K, Bishop WR, Pachter AJ, Wang Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther 2002;1:1349-53.
31. Jiang Y, Rom WN, Yie TA, Chi CX, Tchou-Wong KM. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene 1999;18:6071-7.
32. Chernicky CL, Yi L, Tan H, Gan SU, Ilan J. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 2000;7:384-95.
33. Kull FC Jr, Jacobs S, Su YF, Svoboda ME, Van Wyk JJ, Cuatrecasas P. Monoclonal antibodies to receptors for insulin and somatomedin-C. J Biol Chem 1983;258:6561-6.
34. Li SL, Kato J, Paz IB, Kasuya J, Fujita-Yamaguchi Y. Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor-I receptor. Biochem Biophys Res Commun 1993;196:92-8.
35. Bendig MM, Jones ST. Rodent to human antibodies by CDR-grafing. In: Chiswell DJ, McCafferty J, Hoogenboom H, Eds. Antibody Engineering: a Practical approach, Oxford, UK: IRL Press, Ltd.,1996.
36. Orlandi R, Gussow DH, Jones PT, Winter G. Cloning immunoglobulins variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 1989;86:3833-7.
37. Jones ST, Bendig MM. Rapid PCR-cloning of full-length mouse immunoglobulin variable regions. Biotechnology (NY) 1991;9:88-9 and erratum 1991;9:579.
38. Klobeck HG, Combriato G, Zachau HG. Immunoglobulin genes of the kappa light chain type from two human lymphoid cell lines are closely related. Nucleic Acids Res 1984;12:6995-7006.
39. Klobeck HG, Solomon A, Zachau HG. Contribution of human VKII germ-line genes to light chain diversity. Nature 1984;309:73-6.
40. Sanz I, Kelly P, Williams C, Scholl S, Tucker P, Capra JD. The smaller human VH gene families display remarkably little polymorphism. EMBO J 1989;8:3741-8.
41. Kraus-Berthier L, Jan M, Guilbaud N, Naze M, Pierre A, Atassi G. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin Cancer Res 2000;6:297-304.
42. De Leon DD, Wilson DM, Powers M, Rosenfeld RG. Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells. Growth Factors 1992;6:327-36.
43. Kato H, Faria TN, Stannard B, Roberts CT, LeRoith D. Role of tyrosine kinase activity in signal transduction by insulin-like growth factor-I (IGF-I) receptor. J Biol Chem 1993;268:2655-61.
44. Aapro MS, Harper P, Johnson SA, Vermorken JB. Developments in cytotoxic chemotherapy: advances in treatment utilising vinorelbine. Crit Rev Oncol Hematol 2001;40:251-63.
45. Curran MP, Plosker GL. Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer. Drugs Aging 2002;19:695-721.
46. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
47. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986;5:2503-12.
48. Li SL, Liang SJ, Guo N, Wu AM, Fujita-Yamaguchi Y. Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth. Cancer Immunol Immunother 2000;49:243-52.
49. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003;63:627-35.
50. Resnik JL, Reichart DB, Huey K, Webster NJ, Seely BL. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998;58:1159-64.
51. Dunn SE, Hardman RA, Kari FW, Barrett JC. Insulin-like growth factor 1 (IGF-I) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997;57:2687-93.
52. Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death - proliferative and anti-apoptotic effects. Breast Cancer Res Treat 1999;56:1-10.
53. Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R, Glazer PM. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997;57:3079-83.
54. Baserga R, Sell C, Porcu P, Rubini M. The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Prolif 1994;27:63-71.
55. Rotem-Yehudar R, Galperin E, Horowitz M. Association of insulin-like growth factor 1 receptor with EHD1 and SNAP29. J Biol Chem 2001;276:33054-60.
56. Chow JC, Condorelli G, Smith RJ. Insulin-like growth factor receptor internalization regulates signaling via the Shc/mitogen-activated protein kinase pathway, but not the insulin receptor substrate-1 pathway. J Biol Chem 1998;273:4672-80.
57. Surmacz E, Guvakova MA, Nolan MK, Nicosia RF, Sciacca L. Type I insulin-like growth factor receptor function in breast cancer. Breast Cancer Res Treat 1998;47:255-67.
58. Osborne CK, Coronado EB, Kitten LJ, Arteaga CI, Fuqua SA, Ramasharma K, Marshall M, Li CH. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol 1989; 3:1701-09.
59. Stewart A., Johnson MD, May FE, Westley BR. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 1990;265:21172-78.
60. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 1999;13:787-96.
61. Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 1997;152:39-47.
62. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, Allred DC, Osborne CK. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989;84:1418-23.
63. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990;2:275-80.
64. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-28.
65. Sell C, Baserga R, Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 1995;55:303-6.
66. Rodriguez-Tarduchy G, Collins MK, Garcia I, Lopez-Rivas A. Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells. J. Immunol 1992;149:535-40.
67. Resnicoff M, Burgaud JL, Rotman HL, Abraham D, Baserga R. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res 1995;55:3739-41.
68. Wang L, Ma W, Markovich R, Lee WL, Wang PH. Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells. Endocrinology 1998;139:1354-60.
69. Ozanne B, Richards CS, Hendler F. Overexpression of the EGFR is a hallmark of squamous cell carcinomas. J Pathol 1986;149:9-14.
70. Mendelsohn J, Baselga J. The EGFR family as targets for cancer therapy. Oncogene 2000;19:6550-65.
71. Connolly JM, Rose DP. Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 1994;24:167-75.
72. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Uberall F, Klocker H. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 1999;59:227-33.
73. Coppola D, Ferber A, Miura M, Sell C, D'Ambrosio C, Rubin R, Baserga R. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol 1994;14:4588-95.
74. Pietrzkowski Z, Lammers R, Carpenter G, Soderquist AM, Limardo M, Phillips PD, Ullrich A, Baserga R. Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Diff 1992;3:199-205.
75. Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L, Zhu Z. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with fully human recombinant bispecific antibodies. J Biol Chem 2003 [Epub ahead of print].
76. Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 2002;8:BR521-6.